ESC 365 - CDK4/6 inhibitor ribociclib induces cardiotoxicity through impaired E2F1-regulated spliceosome assembly

Delegates Premium Access

CDK4/6 inhibitor ribociclib induces cardiotoxicity through impaired E2F1-regulated spliceosome assembly

Session: Mechanisms of cancer treatment-related cardiovascular toxicity

Topic: Research and New Technology

Speaker: Ms E. Pet (Groningen, NL)

Event: ESC Cardio-Oncology 2025

Congress Presentation

Add to my library

About the speaker

Ms Eva Pet

University Medical Centre Groningen, Groningen (Netherlands (The))

0 follower

4 more presentations in this session

Targeted cardiac inactivation of Guanylate binding protein 5 (GBP5) protects from cardiotoxicity after radiation

Speaker: Doctor M. Heckmann (Heidelberg, DE)

Cell painting based high-content phenotypic screening to elucidate kinase signaling pathways in ibrutinib-mediated atrial fibrillation

Speaker: Doctor M. Fleming (Nashville, US)

Mismatch between pre-clinical cardio-oncology and clinical oncology research

Speaker: Mr M. Stabile (Genoa, IT)

Early myocardial metabolic signatures of anthracycline-induced cardiotoxicity

Speaker: Mr C. Galan (Madrid, ES)

Access the full session

Mechanisms of cancer treatment-related cardiovascular toxicity

Speakers: Ms E. Pet, Doctor M. Heckmann, Doctor M. Fleming, Mr M. Stabile, Mr C. Galan

About the event

ESC Cardio-Oncology 2025

20 June - 21 June 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources